Related Experiment Video

Updated: Apr 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statin Therapy May not Effect NLR and MPV Levels in Patients With Hypercholesterolemia: A Retrospective Study

Fatih Gungoren1, Feyzullah Besli2, Serhat Caliskan1

  • 1Department of Cardiology, Medical Faculty, Uludag University, Bursa, Turkey.

Angiology
|September 6, 2015
PubMed

Insights

Statins effectively lowered lipids in high-risk patients but did not significantly alter neutrophil-lymphocyte ratio (NLR) or mean platelet volume (MPV). Further research is needed to confirm these findings for cardiovascular disease management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Statins are known for lipid-lowering and potential pleiotropic effects in cardiovascular diseases.
  • Neutrophil-lymphocyte ratio (NLR) and mean platelet volume (MPV) are emerging inflammatory markers associated with cardiovascular risk.
  • The impact of statin therapy on NLR and MPV in patients with coronary artery disease (CAD) or high cardiovascular risk remains unclear.

Purpose of the Study:

  • To investigate the effect of statin therapy on NLR and MPV in patients with hypercholesterolemia and CAD or high cardiovascular risk.
  • To compare baseline NLR and MPV levels between patients and healthy controls.
  • To assess changes in NLR and MPV after 24 weeks of statin treatment.

Main Methods:

  • A retrospective study included 261 patients with hypercholesterolemia and CAD or high CV risk, and 50 healthy controls.
  • Patients received atorvastatin or rosuvastatin for 24 weeks, with dosages adjusted based on lipid levels and CV risk.
  • NLR, MPV, and lipid parameters were measured at baseline and after 24 weeks of treatment.

Main Results:

  • Baseline NLR and MPV were significantly higher in the patient group compared to controls (P < .001 and P = .038, respectively).
  • Statin therapy resulted in significant reductions in lipid levels.
  • No significant changes were observed in NLR or MPV after 24 weeks of statin treatment.

Conclusions:

  • While statins effectively manage lipid profiles in patients with hypercholesterolemia and high cardiovascular risk, they do not appear to significantly alter NLR or MPV.
  • Elevated baseline NLR and MPV in this patient cohort suggest a potential role for these markers in risk stratification.
  • Further prospective studies are warranted to elucidate the precise effects of statin therapy on NLR and MPV in cardiovascular disease.

Keywords:
cardiovascular riskcoronary artery diseasemean platelet volumeneutrophil–lymphocyte ratiostatin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
849
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
426
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
770